BetterLife Pharma Inc. (NPAU.F)
- Previous Close
0.0615 - Open
0.0635 - Bid 0.0625 x --
- Ask 0.0780 x --
- Day's Range
0.0620 - 0.0635 - 52 Week Range
0.0240 - 0.0740 - Volume
1,100 - Avg. Volume
278 - Market Cap (intraday)
7.919M - Beta (5Y Monthly) 1.35
- PE Ratio (TTM)
-- - EPS (TTM)
-0.0100 - Earnings Date May 28, 2024 - Jun 1, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
BetterLife Pharma Inc., a biotechnology company, engages in the development and commercialization of compounds for the treatment of mental disorders in Canada. It is also involved in refining and developing drug candidates from a set of complementary interferon-based technologies that have the potential to engage the immune system to fight virus infections. The company's products pipeline includes BETR-001 for the treatment of major depressive disorder, anxiety, and neuropathic pain and other neuro-psychiatric and neurological disorders; and BETR-002 to treat benzodiazepine dependency, anxiety, and neurodegenerative disorders. It is also developing MM-003, which has completed Phase II clinical trials for treatment of COVID-19 and other respiratory viral infections; and MM-001, a topical cream for local intravaginal use to treat HPV-induced cervical intraepithelial neoplasia that has completed Phase II clinical trials. The company was formerly known as Pivot Pharmaceuticals Inc. and changed its name to BetterLife Pharma Inc. in December 2019. BetterLife Pharma Inc. was incorporated in 2002 and is headquartered in Vancouver, Canada.
www.abetterlifepharma.comRecent News: NPAU.F
Performance Overview: NPAU.F
Trailing total returns as of 4/26/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NPAU.F
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NPAU.F
Valuation Measures
Market Cap
7.92M
Enterprise Value
8.29M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
-3.00
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-500.76%
Return on Equity (ttm)
--
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-2.57M
Diluted EPS (ttm)
-0.0100
Balance Sheet and Cash Flow
Total Cash (mrq)
92.62k
Total Debt/Equity (mrq)
--
Levered Free Cash Flow (ttm)
-2.16M
Company Insights: NPAU.F
NPAU.F does not have Company Insights